Cormedix Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cormedix Inc. on March 22, 2013, covering events that occurred on March 20, 2013. The company is focused on the commercialization of its product, Neutrolin.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The report focuses exclusively on corporate governance and compensation matters.
Material Changes
- 2013 Stock Incentive Plan Approval: The Board approved a new plan reserving 5,000,000 shares of common stock for equity grants (options, restricted stock, awards) to directors, officers, employees, and consultants. This replaces the 2006 Plan, which had only 401,703 shares remaining.
- Stock Option Grants: On March 20, 2013, the company granted non-statutory stock options covering 1,400,000 shares to team members and directors.
- Vesting Conditions: Most options vest based on performance milestones related to Neutrolin commercialization over one to three years. Director options vest over two years without performance milestones.
- Contingency: These specific grants will terminate if stockholders do not approve the 2013 Plan.
- Allocation: Randy Milby (500,000), Antony Pfaffle (210,000), Steve Lefkowitz (120,000), Matthew Duffy (100,000), Gary Gelbfish (50,000), and Rich Cohen (40,000).
- Executive Compensation: CEO Randy Milby's annual salary was increased to $250,000, effective April 1, 2013.
Guidance, Outlook, and Risks
The Board intends to submit the 2013 Stock Incentive Plan to stockholders for approval at the 2013 Annual Meeting of Stockholders, the date of which is undetermined. The plan must be approved within 12 months. Until approval, no further awards will be made under the 2006 Plan. The filing highlights the risk that the new option grants are contingent upon shareholder approval of the new plan.
Investor Verification Checklist
- Verify the date and outcome of the 2013 Annual Meeting of Stockholders regarding the 2013 Plan approval.
- Confirm the specific performance milestones required for the vesting of the 1,400,000 granted options.
- Review the upcoming Form 10-K for the full text of the 2013 Stock Incentive Plan.
- Monitor the status of the 2006 Plan to ensure no further grants are issued pending the new plan's approval.